Mamilla, Marcos M.
HRN: 20-99-40 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
09/26/2022
CLINDAMYCIN 150MG/ML, 4ML (AMP)
09/26/2022
10/09/2022
IV
600mg
Q6
Cellulitis
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes